



**ICH Topic S 7 A
Safety Pharmacology Studies for Human Pharmaceuticals**

Step 5

**NOTE FOR GUIDANCE ON SAFETY PHARMACOLOGY STUDIES
FOR HUMAN PHARMACEUTICALS
(CPMP/ICH/539/00)**

| | |
|------------------------------------|---------------|
| TRANSMISSION TO CPMP | March 2000 |
| TRANSMISSION TO INTERESTED PARTIES | March 2000 |
| DEADLINE FOR COMMENTS | November 2000 |
| APPROVAL BY CPMP | November 2000 |
| DATE FOR COMING INTO OPERATION | June 2001 |

NOTE FOR GUIDANCE ON SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS

1. INTRODUCTION

1.1 Objectives Of The Guideline

This guideline was developed to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources.

This guideline provides a definition, general principles and recommendations for safety pharmacology studies.

1.2 Background

Pharmacology studies have been performed worldwide for many years as part of the non-clinical evaluation of pharmaceuticals for human use. There have been, however, no internationally accepted definitions, objectives or recommendations on the design and conduct of safety pharmacology studies. (Note 1)

The term “safety pharmacology studies” first appeared in the ICH topics, “Timing of Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (M3)” and “Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (S6)” as studies that should be conducted to support use of therapeutics in humans (1, 2). Details of the safety pharmacology studies, including their definition and objectives, were left for future discussion.

1.3 Scope Of The Guideline

This guideline generally applies to new chemical entities and biotechnology-derived products for human use. This guideline can be applied to marketed pharmaceuticals when appropriate (e.g. when adverse clinical events, a new patient population, or a new route of administration raises concerns not previously addressed).

1.4 General Principle

It is important to adopt a rational approach when selecting and conducting safety pharmacology studies. The specific studies that should be conducted and their design will vary based on the individual properties and intended uses of the pharmaceuticals. Scientifically valid methods should be used, and when there are internationally recognized methods that are applicable to pharmaceuticals, these are preferable. Moreover, the use of new technologies and methodologies in accordance with sound scientific principles is encouraged.

Some safety pharmacology endpoints can be incorporated in the design of toxicology, kinetic, clinical studies, etc., while in other cases these endpoints should be evaluated in specific safety pharmacology studies. Although adverse effects of a substance may be detectable at exposures that fall within the therapeutic range in appropriately designed safety pharmacology studies, they may not be evident from observations and measurements used to detect toxicity in conventional animal toxicity studies.

1.5 Definition Of Safety Pharmacology

Pharmacology studies can be divided into three categories: primary pharmacodynamic, secondary pharmacodynamic and safety pharmacology studies.

For the purpose of this document, safety pharmacology studies are defined as those studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above. (See Note 2 for definitions of primary pharmacodynamic and secondary pharmacodynamic studies.)

In some cases, information on the primary and secondary pharmacodynamic properties of the substance may contribute to the safety evaluation for potential adverse effect(s) in humans and should be considered along with the findings of safety pharmacology studies.

2. GUIDELINE

2.1 Objectives Of Studies

The objectives of safety pharmacology studies are: 1) to identify undesirable pharmacodynamic properties of a substance that may have relevance to its human safety; 2) to evaluate adverse pharmacodynamic and/or pathophysiological effects of a substance observed in toxicology and/or clinical studies; and 3) to investigate the mechanism of the adverse pharmacodynamic effects observed and/or suspected. The investigational plan to meet these objectives should be clearly identified and delineated.

2.2 General Considerations In Selection And Design Of Safety Pharmacology Studies

Since pharmacological effects vary depending on the specific properties of each test substance, the studies should be selected and designed accordingly. The following factors should be considered (the list is not comprehensive):

- (1) Effects related to the therapeutic class of the test substance, since the mechanism of action may suggest specific adverse effects (e.g., proarrhythmia is a common feature of antiarrhythmic agents);
- (2) Adverse effects associated with members of the chemical or therapeutic class, but independent of the primary pharmacodynamic effects (e.g., anti-psychotics and QT prolongation);
- (3) Ligand binding or enzyme assay data suggesting a potential for adverse effects;
- (4) Results from previous safety pharmacology studies, from secondary pharmacodynamic studies, from toxicology studies, or from human use that warrant further investigation to establish and characterize the relevance of these findings to potential adverse effects in humans.

During early development, sufficient information (e.g., comparative metabolism) may not always be available to rationally select or design the studies in accordance with the points stated above; in such circumstances, a more general approach in safety pharmacology investigations can be applied.

A hierarchy of organ systems can be developed according to their importance with respect to life-supporting functions. Vital organs or systems, the functions of which are acutely critical for life, such as the cardiovascular, respiratory and central nervous systems, are considered to be the most important ones to assess in safety pharmacology studies. Other organ systems, such as the renal or gastrointestinal system, the functions of which can be transiently disrupted by adverse pharmacodynamic effects without causing irreversible harm, are of less immediate investigative concern. Safety pharmacology evaluation of effects on these other systems may

be of particular importance when considering factors such as the likely clinical trial or patient population (e.g. gastrointestinal tract in Crohn's disease, renal function in primary renal hypertension, immune system in immunocompromised patients.).

2.3 Test Systems

2.3.1 General Considerations On Test Systems

Consideration should be given to the selection of relevant animal models or other test systems so that scientifically valid information can be derived. Selection factors can include the pharmacodynamic responsiveness of the model, pharmacokinetic profile, species, strain, gender and age of the experimental animals, the susceptibility, sensitivity, and reproducibility of the test system and available background data on the substance. Data from humans (e.g., in vitro metabolism), when available, should also be considered in the test system selection. The time points for the measurements should be based on pharmacodynamic and pharmacokinetic considerations. Justification should be provided for the selection of the particular animal model or test system.

2.3.2 Use Of In Vivo And In Vitro Studies

Animal models as well as ex vivo and in vitro preparations can be used as test systems. Ex vivo and in vitro systems can include, but are not limited to: isolated organs and tissues, cell cultures, cellular fragments, subcellular organelles, receptors, ion channels, transporters and enzymes. In vitro systems can be used in supportive studies (e.g., to obtain a profile of the activity of the substance or to investigate the mechanism of effects observed in vivo).

In conducting in vivo studies, it is preferable to use unanesthetized animals. Data from unrestrained animals that may be chronically instrumented for telemetry, other suitable instrumentation methods for conscious animals, or animals conditioned to the laboratory environment are preferable to data from restrained or unconditioned animals. In the use of unanesthetized animals, the avoidance of discomfort or pain is a foremost consideration.

2.3.3 Experimental Design

2.3.3.1 Sample Size And Use Of Controls

The size of the groups should be sufficient to allow meaningful scientific interpretation of the data generated. Thus, the number of animals or isolated preparations should be adequate to demonstrate or rule out the presence of a biologically significant effect of the test substance. This should take into consideration the size of the biological effect that is of concern for humans. Appropriate negative and positive control groups should be included in the experimental design. In well-characterized in vivo test systems, positive controls may not be necessary. The exclusion of controls from studies should be justified.

2.3.3.2 Route Of Administration

In general, the expected clinical route of administration should be used when feasible. Regardless of the route of administration, exposure to the parent substance and its major metabolites should be similar to or greater than that achieved in humans when such information is available. Assessment of effects by more than one route may be appropriate if the test substance is intended for clinical use by more than one route of administration (e.g. oral and parenteral), or where there are observed or anticipated significant qualitative and quantitative differences in systemic or local exposure.

2.4 Dose Levels Or Concentrations Of Test Substance

2.4.1 In Vivo Studies

Safety pharmacology studies should be designed to define the dose-response relationship of the adverse effect observed. The time course (e.g., onset and duration of response) of the adverse effect should be investigated, when feasible. Generally, the doses eliciting the adverse effect should be compared to the doses eliciting the primary pharmacodynamic effect in the test species or the proposed therapeutic effect in humans, if feasible. It is recognized that there are species differences in pharmacodynamic sensitivity. Therefore, doses should include and exceed the primary pharmacodynamic or therapeutic range. In the absence of an adverse effect on the safety pharmacology parameter(s) evaluated in the study, the highest tested dose should be a dose that produces moderate adverse effects in this or in other studies of similar route and duration. These adverse effects can include dose-limiting pharmacodynamic effects or other toxicity. In practice, some effects in the toxic range (e.g., tremors or fasciculation during ECG recording) may confound the interpretation of the results and may also limit dose levels. Testing of a single group at the limiting dose as described above may be sufficient in the absence of an adverse effect on safety pharmacology endpoints in the test species.

2.4.2 In Vitro Studies

In vitro studies should be designed to establish a concentration-effect relationship. The range of concentrations used should be selected to increase the likelihood of detecting an effect on the test system. The upper limit of this range may be influenced by physico-chemical properties of the test substance and other assay specific factors. In the absence of an effect, the range of concentrations selected should be justified.

2.5 Duration Of Studies

Safety pharmacology studies are generally performed by single dose administration. When pharmacodynamic effects occur only after a certain duration of treatment, or when results from repeat dose non-clinical studies or results from use in humans give rise to concerns about safety pharmacological effects, the duration of the safety pharmacology studies to address these effects should be rationally based.

2.6 Studies On Metabolites, Isomers And Finished Products

Generally, any parent compound and its major metabolite(s) that achieve, or are expected to achieve, systemic exposure in humans should be evaluated in safety pharmacology studies. Evaluation of major metabolites is often accomplished through studies of the parent compound in animals. If the major human metabolite(s) is (are) found to be absent or present only at relatively low concentrations in animals, assessment of the effects of such metabolite(s) on safety pharmacology endpoints should be considered. Additionally, if metabolites from humans are known to substantially contribute to the pharmacological actions of the therapeutic agent, it may be important to test such active metabolites. When the in vivo studies on the parent compound have not adequately assessed metabolites, as discussed above, the tests of metabolites can use in vitro systems based on practical considerations.

In vitro or in vivo testing of the individual isomers should also be considered when the product contains an isomeric mixture.

Safety pharmacology studies with the finished product formulation(s) should be conducted only for formulations that substantially alter the pharmacokinetics and/or pharmacodynamics of the active substance in comparison to formulations previously tested (i.e. through active excipients such as penetration enhancers, liposomes, and other changes such as polymorphism).

2.7 Safety Pharmacology Core Battery

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.